Financials in USD. Standardized financial statements.
A compact view of how Maravai LifeSciences Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $185.74M | $259.19M | $288.94M | $883.00M | $799.24M | $284.10M | $143.14M | $123.83M |
| Revenue Growth? | -28.3% | -10.3% | -67.3% | +10.5% | +181.3% | +98.5% | +15.6% | 0.0% |
| Cost of Revenue? | $152.35M | $150.88M | $148.74M | $168.96M | $140.56M | $79.65M | $66.85M | $60.77M |
| Gross Profit? | $33.39M | $108.31M | $140.20M | $714.04M | $658.68M | $204.45M | $76.29M | $63.07M |
| Gross Margin? | +18.0% | +41.8% | +48.5% | +80.9% | +82.4% | +72.0% | +53.3% | +50.9% |
| Operating Expenses? | $40.13M | $343.93M | $171.85M | $139.83M | $104.03M | $84.55M | $52.30M | $45.69M |
| Operating Income? | -$6.74M | -$235.62M | -$31.65M | $574.22M | $554.64M | $119.90M | $23.99M | $16.44M |
| EBITDA? | -$147.11M | -$156.92M | $712.41M | $609.99M | $585.78M | $138.27M | $48.19M | $33.25M |
| Income Before Tax | -$234.97M | -$261.48M | $617.74M | $551.47M | $530.76M | $81.70M | -$5.85M | -$16.50M |
| Income Tax Expense | -$4.21M | -$1.86M | $756.11M | $60.81M | $61.52M | $2.88M | -$652,000 | $417,000 |
| Net Income? | -$130.77M | -$144.85M | -$119.03M | $220.21M | $182.04M | $76.89M | -$8.49M | -$17.73M |
| EPS? | $-0.91 | $-1.05 | $-0.90 | $1.67 | $1.59 | $7.43 | $-0.05 | $-0.20 |
| Diluted EPS? | $-0.91 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 | $-0.05 | $-0.20 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality